The Efficacy and Safety of Different Dosages of Rituximab for Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis

CONCLUSION: Rituximab was effective and safe for adult patients with ITP. A low-dose rituximab regimen might be an effective alternative to the standard-dose regimen in ITP, as it showed similar CRR, ORR, and SRR at month 12 and was relatively safer with a lower cost.PMID:34660807 | PMC:PMC8514896 | DOI:10.1155/2021/9992086
Source: Biomed Res - Category: Research Authors: Source Type: research